Synaptic effects of antidepressants

Journal of Clinical Psychopharmacology

Volumn 16, Issue 3 SUPPL. 2, 1996, Pages

  Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); AMITRIPTYLINE; AMOXAPINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATROPINE; CHLORPROMAZINE; CLOMIPRAMINE; DESIPRAMINE; DIPHENHYDRAMINE; DOPAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; NEFAZODONE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PHENTOLAMINE; PROTRIPTYLINE; SEROTONIN; SERTRALINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ARTICLE; DEPRESSION; HUMAN; PRIORITY JOURNAL; SYNAPSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOPAMINE; DRUG INTERACTIONS; HUMANS; NOREPINEPHRINE; RECEPTORS, NEUROTRANSMITTER; SEROTONIN; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 0029996915     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199606002-00001     Document Type: Article

References (9)

1. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52[6, suppl]:4-10.
2. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-81.
3. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984;104:277-86.
4. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-9.
5. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984;230:94-102.
6. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-65.
7. Troy SM, Parker VD, Fruncillo RJ, Chiang ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995;35:404-9.
8. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-9.
9. Glassman AH, Bigger JT Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry 1981;38:815-20.